Arbekacin

An aminoglycoside antibiotic used in the treatment of bacterial infections

Arbekacin

File:Arbekacin structure.svg

Chemical structure of Arbekacin

Arbekacin is an aminoglycoside antibiotic that is used primarily in the treatment of infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is a semi-synthetic derivative of kanamycin, which is another aminoglycoside antibiotic.

Mechanism of action

Arbekacin works by binding to the bacterial ribosome, specifically the 30S subunit, and inhibiting protein synthesis. This action is bactericidal, meaning it kills the bacteria rather than merely inhibiting its growth. The binding of arbekacin to the ribosome interferes with the initiation complex of protein synthesis and causes misreading of mRNA, leading to the production of nonfunctional or toxic peptides.

Clinical use

Arbekacin is primarily used in the treatment of infections caused by resistant strains of bacteria, such as MRSA. It is often reserved for cases where other antibiotics are ineffective due to resistance. Arbekacin is administered intravenously, and its use is typically limited to hospital settings.

Side effects

As with other aminoglycosides, arbekacin can cause nephrotoxicity and ototoxicity. Nephrotoxicity refers to kidney damage, while ototoxicity refers to damage to the ear, which can result in hearing loss or balance issues. Monitoring of drug levels and kidney function is important during treatment to minimize these risks.

Pharmacokinetics

Arbekacin is not absorbed from the gastrointestinal tract, so it must be administered parenterally. It is distributed widely in the body and is excreted primarily by the kidneys. The half-life of arbekacin can be prolonged in patients with renal impairment, necessitating dose adjustments.

Related pages

• Aminoglycoside
• Antibiotic resistance
• Methicillin-resistant Staphylococcus aureus
• Kanamycin